ADC Therapeutics SA (NYSE: ADCT) Given the average “buy” recommendation by brokerage firms

0


Shares of ADC Therapeutics SA (NYSE: ADCT) have received a consensus recommendation to “Buy” from the six research companies that currently cover the company, Marketbeat reports. One analyst rated the stock with a sell recommendation, another assigned a hold recommendation, and four gave the company a buy recommendation. The one-year average price target among analysts who hedged the stock in the past year is $ 44.60.

ADCT has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” note and set a target price of $ 55.00 for ADC Therapeutics shares in a research report released on Tuesday, August 10. The Royal Bank of Canada began covering ADC Therapeutics in a research report on Monday, August 9. They set an “outperformance” rating and a price target of $ 33.00 for the stock. Cantor Fitzgerald began covering ADC Therapeutics in a research report on Tuesday, June 15. They set an “overweight” rating and a target price of $ 46.00 for the stock. Morgan Stanley lowered its price target on ADC Therapeutics from $ 51.00 to $ 47.00 and set an “overweight” rating on the stock in a research report published on Tuesday, September 7. Ultimately, Zacks investment research downgraded ADC Therapeutics from a “hold” rating to a “sell” rating in a research report released Tuesday, August 31.

Institutional investors and hedge funds have recently changed their holdings in the company. Magnetar Financial LLC increased its equity stake in ADC Therapeutics by 27.2% in the 2nd quarter. Magnetar Financial LLC now owns 140,198 shares of the company valued at $ 3,414,000 after purchasing an additional 30,000 shares in the last quarter. JPMorgan Chase & Co. increased its stake in ADC Therapeutics by 5.2% during the 1st quarter. JPMorgan Chase & Co. now owns 3,142,253 shares of the company valued at $ 76,702,000 after purchasing an additional 155,335 shares last quarter. SG Americas Securities LLC acquired a new stake in ADC Therapeutics during the 1st quarter for a value of $ 122,000. Caption Management LLC acquired a new stake in ADC Therapeutics during the 1st quarter for a value of $ 2,026,000. Finally, Employees Retirement System of Texas acquired a new stake in ADC Therapeutics during the 1st quarter for a value of $ 3,295,000. 48.64% of the shares are held by institutional investors and hedge funds.

(A d)

This could be the most underrated stock available. Look at it closely.

Actions of ADCT action open for $ 29.69 Tuesday. The company has a debt to equity ratio of 0.55, a rapid ratio of 7.51, and a current ratio of 7.66. The company has a market cap of $ 2.05 billion, a PE ratio of -11.25 and a beta of 2.47. The stock has a fifty day moving average of $ 26.02 and a two hundred day moving average of $ 24.58. ADC Therapeutics has a one-year minimum of $ 20.01 and a one-year maximum of $ 38.34.

ADC Therapeutics (NYSE: ADCT) last reported its quarterly results on Monday, August 2. The company reported ($ 0.96) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($ 0.86) by ($ 0.10). Equity research analysts predict that ADC Therapeutics will post earnings per share of -3.58 for the current fiscal year.

ADC Therapeutics Company Profile

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody-drug conjugates (ADCs) for patients with blood malignancies and solid tumors. Its main product candidates are loncastuximab tesirine (ADCT-402), an ADC undergoing a Phase II clinical trial for the treatment of diffuse large B-cell lymphoma (DLBCL) and relapsed or refractory follicular lymphoma. , and a phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as a phase I / II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and lymphoma in mantle cells; and camidanlumab tesirine (ADCT-301), an ADC undergoing a pivotal phase II clinical trial for the treatment of relapsed or refractory Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, and a phase Ib clinical trial for some advanced solid tumors.

Recommended Story: How To Calculate The Annual Depreciation Rate

Analyst Recommendations for ADC Therapeutics (NYSE: ADCT)

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in ADC Therapeutics now?

Before you consider ADC Therapeutics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the larger market takes hold of… and ADC Therapeutics was not on the list.

While ADC Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here


Leave A Reply

Your email address will not be published.